Emerging evidence from pancreatic cancer models shows that stromal-derived LIF acts in a paracrine manner to promote tumor progression, and that LIFR blockade enhances response to chemotherapy [11]. This evidence concerns the gene LIF and familial pancreatic carcinoma.